• J. Spranger
Living reference work entry
Part of the Springer Reference Medizin book series (SRM)


Mukopolysaccharidosen (MPS) sind erbliche, progrediente Speicherkrankheiten, hervorgerufen durch die intrazelluläre Anhäufung von Glykosaminoglykanen (sauren Mukopolysacchariden). Glykosaminoglykane sind komplexe Kohlenhydratketten aus Uronsäuren, Aminozuckern und Neutralzuckern. Die wichtigsten sind Chondroitin-4-sulfat, Chondroitin-6-sulfat, Heparansulfat, Dermatansulfat, Keratansulfat und Hyaluronan. Sie werden intrazellulär synthetisiert, überwiegend in den Extrazellulärraum ausgeschieden und teilweise in Lysosomen wieder abgebaut. Im Gewebe sind sie mit Proteinen zu großmolekularen Proteoglykanen verbunden.


  1. Arvio M, Sauna-aho O, Peippo M (2001) Bone marrow transplanation for aspartylglucosaminuria: follow-up study of transplanted and non-transplanted patients. J Pediatr 138:288–290PubMedCrossRefGoogle Scholar
  2. Beck M (2010) Therapy for lysosomal storage disorders. Life 62:33–40PubMedGoogle Scholar
  3. Ben Turkia H, Tebib N, Azzouz H et al (2008) Phenotypic spectrum of fucosidosis in Tunisia. J Inherit Metab Dis Suppl 2:313–316CrossRefGoogle Scholar
  4. Berger KI, Fagondes SC, Guigliani R et al (2013) Respiratory and sleep disorders in mucopolysaccharidosis. J Inherit Metab Dis 36:201–221PubMedPubMedCentralCrossRefGoogle Scholar
  5. Bonten EJ, Arts WF, Beck M et al (2000) Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. Hum Mol Genet 9:2715–2725PubMedCrossRefGoogle Scholar
  6. Brunetti-Pierri N, Scaglia F (2008) GM1 gangliosidosis; review of clinical, molecular, and therapeutic aspects. Mol Genet Metab 94:391–396PubMedCrossRefGoogle Scholar
  7. Busche A, Hennermann JB, Bürger F (2009) Neonatal manifestation of multiple sulfatase deficiency. Eur J Pediatr 168:969–973PubMedCrossRefGoogle Scholar
  8. Caciotti A, Garman SC, Rivera-Colón Y (2011) GM1 gangliosidosis and Morquio B disease. Biochim Biophys Acta 182:782–790CrossRefGoogle Scholar
  9. Cathey SS, Leroy JG, Wood T et al (2011) Phenotype and genotype in mucolipidosis II and III alpha/beta: a study of 61 probands. J Med Genet 47:38–48CrossRefGoogle Scholar
  10. Chen YT (2001) Glycogen storage diseases. In: Sly WS, Valle D, Scriver CR, Beaudet A (Hrsg) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, S 1521–1551Google Scholar
  11. Chou JY, Raben N (Hrsg) (2002) Glycogen storage diseases (GSDs). Curr Mol Med 2:101–227Google Scholar
  12. Chou JY, Jun HS, Mansfield BC (2010) Neutropenia in type Ib glycogen storage disease. Curr Opin Hematol 17:36–42PubMedPubMedCentralCrossRefGoogle Scholar
  13. Cleary MA, Wraith JE (1993) Management of mucopolysaccharidosis type III. Arch Dis Child 69:403–406PubMedPubMedCentralCrossRefGoogle Scholar
  14. Coutinho MF, Lacerda L, Alves S (2012) Glycosaminoglycan storage disorders: a review. Biochem Res Int 2012:471325. doi:10.1155/2012/471325PubMedPubMedCentralCrossRefGoogle Scholar
  15. Darin N, Kyllerman M, Hard AL (2009) Juvenile gala tosialidosis with attacks of neuropathic pain and absence of sialyloligosacchariduria. Eur J Paediatr Neurol 13:553–555PubMedCrossRefGoogle Scholar
  16. Däublin G, Schwahn B, Wendel U (2002) Type I glycogen storage disease: favourable outcome on a strict management regimen avoiding increased lactate production during childhood and adolescence. Eur J Pediatr 161(Suppl 1):40–45CrossRefGoogle Scholar
  17. Davis MK, Weinstein DA (2008) Liver transplantation in children with glycogen storage disease: controversies and evaluation of the risk/benefit of this procedure. Pediatr Transplant 12:137–145PubMedCrossRefGoogle Scholar
  18. De Ru MH, Boelens JJ, Das AM et al (2011) Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis 6:55PubMedPubMedCentralCrossRefGoogle Scholar
  19. Dierks T, Schmidt B, Borissenko LV (2003) Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C-alpha-formyl-glycine generating enzyme. Cell 113:435–444PubMedCrossRefGoogle Scholar
  20. DiMauro S, Spiegel R (2011) Progress and problems in muscle glycogenoses. Acta Myol 30:96–102PubMedPubMedCentralGoogle Scholar
  21. Eisengart JB, Rudser KD, Tolar J et al (2013) Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler Syndrome. J Pediatr 162:375–380PubMedPubMedCentralCrossRefGoogle Scholar
  22. Frawley G, Fuenzalida D, Donath S et al (2012) A retrospective audit of anesthetic techniques and complications in children with mucopolysaccharidoses. Pediatr Anesth 22:73–44CrossRefGoogle Scholar
  23. Grewal SS, Shapiro EG, Krivit WE et al (2004) Effective treatment of alpha mannosidosis by allogeneic hematopoietic stem cell transplantation. J Pediatr 144:569–573PubMedCrossRefGoogle Scholar
  24. Guffon N, Bertrand Y, Forest I et al (2009) Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr 154:733–737PubMedCrossRefGoogle Scholar
  25. Harmatz P, Giugliani R, Schwartz IV et al (2008) Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI. Mol Genet Metab 94:469–475PubMedCrossRefGoogle Scholar
  26. Kampmann C, Beck M, Morin I, Loehr JP (2011) Prevalence and characterization of cardiac involvement in Hunter syndrome. J Pediatr 159:327–331PubMedCrossRefGoogle Scholar
  27. Kishnani P, Chen YT (2011) Disorders of glycogen metabolism. In: Rudolph CD, Rudolph AM, Lister GE et al (Hrsg) Rudolph’s pediatrics. 22. Aufl. McGraw Hill, New York, S 599–607Google Scholar
  28. Kishnani PS, Corzo D, Leslie ND et al (2009) Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 66:329–335PubMedPubMedCentralCrossRefGoogle Scholar
  29. Laforêt P, Weinstein D, Smit GPA (2011) The glycogen storage diseases and related disorders. In: Saudubray JM, van den Berghe G, Walter JH (Hrsg) Inborn metabolic diseases. 5. Aufl. Springer, Berlin, S 115–139Google Scholar
  30. Leroy JG (2012) Sialuria. In: Pagon RA, Bird TD, Dolan CR, Stephens K (Hrsg) Gene reviews. University of Washington, Seattle. Zugegriffen am 07.02.2013
  31. Maheshwari A, Rankin R, Segev DL, Thuluvath PJ (2012) Outcomes of liver transplantation for glycogen storage disease: a matched-control study and a review of literature. Clin Transplant 26:432–436PubMedCrossRefGoogle Scholar
  32. Malm D, Nilsssen O (2012) Alpha-Mannosidosis. In: Pagon RA, Bird TD, Dolan CR, Stephens K (Hrsg) Gene reviews. University of Washington, Seattle. Zugegriffen am 07.02.2013
  33. Martens DH, Rake JP, Navis G, Fidler V, van Dael CM, Smit GPA (2009) Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition. Clin J Am Soc Nephrol 4:1741–1746PubMedPubMedCentralCrossRefGoogle Scholar
  34. Muenzer J, Wraith JE, Clarke LA (2009) Mucopolysaccharidosis I: management and treatment guidelines. J Pediatr 123:19–29CrossRefGoogle Scholar
  35. Muenzer J, Beck M, Eng CM (2011) Long-term, open-labeled extension study of idursulfatase in the treatment of Hunter syndrome. Genet Med 13:95–101PubMedCrossRefGoogle Scholar
  36. Mynarek M, Tolar J, Albert MH et al (2012) Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients. Bone Marrow Transplant 47:352–359PubMedCrossRefGoogle Scholar
  37. Rake JP, Visser G, Labrune P et al (2002) Guidelines for management of glycogen storage disease type I – European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 161(Suppl 1):112–119CrossRefGoogle Scholar
  38. Rust S, Tegtmeyer LC, Fingerhut R, Freeze HH, Marquart T (2012) Phosphoglucomuase-1-defects of the gatekeeper between glycogen and glucose strongly impair protein glycosylation with diversity of phenotypes – mechanism, screening, treatment. J Inherit Metab Dis 35(Suppl 1):16Google Scholar
  39. Santer R, Ullrich K (2004) Cardiac involvement of glycogen storage diseases. In: Böhles H, Sewell AC (Hrsg) Metabolic cardiomyopathy. Medpharm, Stuttgart, S 47–65Google Scholar
  40. Scarpa M, Almásy Z, Beck M (2011) Mucopolysaccharidosis type II. European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rar Dis 6:72CrossRefGoogle Scholar
  41. Sedel F, Friderici K, Nummy K (2006) Atypical Gilles de la Tourette syndrome with beta-mannosidase deficiency. Arch Neurol 63:129–131PubMedCrossRefGoogle Scholar
  42. Smit GPA, Ververs MT, Belderok B, van Rijn M, Berger R, Fernandes J (1990) Long-term outcome of patients with glycogen storage diseases. J Inherit Metab Dis 13:411–418PubMedCrossRefGoogle Scholar
  43. Sohn YB, Park SW, Kim SH (2012) Enzyme replacement therapy improves joint motion and outcome of the 12-min walk test in a mucopolysacharidosis type VI patient previously treated with bone marrow transplantation. Am J Med Genet 158A:1158–1163PubMedCrossRefGoogle Scholar
  44. Tomatsu S, Montano AM, Oikawa H et al (2011) Mucopolysaccharidosis type IVA (Morquio A disease) clinical review and current treatment. Curr Pharm Biotechnol 12:931–945PubMedCrossRefGoogle Scholar
  45. Turbeville S, Nicely H, Rizzo JD (2011) Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI. Mol Genet Metab 102:111–115PubMedPubMedCentralCrossRefGoogle Scholar
  46. Valavannopoulos V, Nicely H, Harmatz P, Turbeville S (2010) Mucopolysaccharidosis VI. Orphanet J Rare Dis 15:5CrossRefGoogle Scholar
  47. Valstar MJ, Marchal JP, Grootenhuis M et al (2011) Cognitive development in patients with mucopolysaccharidosis type III (Sanfilippo syndrome). Orphanet J Rare Dis 6:43PubMedPubMedCentralCrossRefGoogle Scholar
  48. Willems PJ, Seo HC, Coucke P et al (1999) Spectrum of mutations in fucosidosis. Eur J Hum Genet 7:60–67PubMedCrossRefGoogle Scholar
  49. Wraith JE, Scarpa M, Beck M (2008) Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267–277PubMedPubMedCentralCrossRefGoogle Scholar
  50. Wraith RF, Mercer J, Page J et al (2009) Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I. J Pediatr 154:135–139PubMedCrossRefGoogle Scholar
  51. Zhou XY, van der Spoel A, Rottier R et al (1996) Molecular and biochemical analysis of protective protein/cathepsin a mutations: correlation with clinical severity in galactosialidosis. Hum Mol Genet 5:1977–1987PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.SinzheimDeutschland

Personalised recommendations